The Weekly Litigation News Digest is now live. Subscribe now

Biogen competitive analysis

Loading summary...

Explore patent oppositions filed by Biogen against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

Liquid Pharmaceutical CompositionFRESENIUS KABI DEUTSCHLANDOct 5, 2022
Liquid Pharmaceutical CompositionARES TRADINGJul 22, 2020
Pharmaceutical Anti-Tnf-Alpha Antibody FormulationRICHTER GEDEON NYRTJun 19, 2019
Liquid Pharmaceutical CompositionARES TRADINGMar 26, 2019

Explore Biogen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
Apr 9, 2025Assay For Jc Virus Antibodies1
Mar 26, 2025Methods Of Preventing And Removing Trisulfide Bonds3
Oct 2, 2024Methods And Products For Evaluating An Immune Response To A Therapeutic Agent1
Apr 3, 2024Control Of Protein Glycosylation By Culture Medium Supplementation And Cell Culture Process Parameters1
Jan 24, 2024Optimized Factor Viii Gene1
Nov 22, 2023Methods Of Treating Or Preventing Spinal Muscular Atrophy5
Oct 18, 2023A Limiter For A Dispensing Device2
Apr 26, 2023Use Of Raman Spectroscopy To Monitor Culture Medium2
Dec 14, 2022Assay For Jc Virus Antibodies1
Nov 30, 2022Method Of Assessing Risk Of Pml2

Latest PTAB cases involving Biogen

Discover the latest PTAB cases involving Biogen, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 14, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Biogen

PGR2022-00054Jul 29, 2022SANDOZBIOGEN MAInstitution Denied
IPR2019-00789Mar 5, 2019SAWAI USABIOGEN MATerminated
IPR2018-01403Jul 13, 2018MYLAN PHARMACEUTICALSBIOGEN MATerminated
IPR2018-00285Dec 14, 2017PFIZERBIOGENTerminated-Settled
IPR2018-00186Dec 1, 2017PFIZERBIOGENTerminated-Settled
IPR2018-00231Dec 1, 2017PFIZERBIOGENTerminated
IPR2018-00086Nov 2, 2017PFIZERBIOGENInstitution Denied
IPR2017-01168Apr 28, 2017PFIZERBIOGENFinal Written Decision
IPR2017-01167Apr 27, 2017PFIZERBIOGENInstitution Denied
IPR2017-01166Apr 21, 2017PFIZERBIOGENInstitution Denied

Peer Comparison New

IP litigation analysis comparing Biogen with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BIOGEN MA - 52 - 7
PHARMACEUTICAL WORKS POLPHARMA3 - - -
POLPHARMA BIOLOGICS9 - - -
SANDOZ1191619 -